Japan's Daiichi Sankyo revamps operations, management, ahead of olmesartan expiry

SINGAPORE--Daiichi Sankyo has revamped management roles and will cut reporting lines on April 1, ahead of the looming loss of its patent protection of flagship hypertension drug olmesartan (Benicar) in key markets this year to shore up its group structure.

Daiichi Sankyo CEO Joji Nakayama

The changes see a "3 Division Structure," consisting of "Corporate Strategy Division," "Corporate Management Division," and "General Affairs & Human Resources Division." The means the "Legal Affairs & CSR Division" will be replaced and the "Secretariat Department" and "Internal Audit Department" will report directly to President and CEO Joji Nakayama "as robust supporting functions to top management."

The structure changes to operations follow a similar shakeup in management roles across the firm and after it last year exited India's Ranbaxy Laboratories through a deal in April to sell it to India's Sun Pharmaceuticals.

- read about the organization changes in this press release
- and the management changes in here